JOURNAL OF IMMUNOTHERAPY

Note: The following journal information is for reference only. Please check the journal website for updated information prior to submission.

Journal Title

J IMMUNOTHER

ISSN / eISSN

1524-9557 / 1537-4513

Aims and Scope

Journal of Immunotherapy features rapid publication of articles on immunomodulators, lymphokines, antibodies, cells, and cell products in cancer biology and therapy. Laboratory and preclinical studies, as well as investigative clinical reports, are presented. The journal emphasizes basic mechanisms and methods for the rapid transfer of technology from the laboratory to the clinic. JIT contains full-length articles, review articles, and short communications.

Subject Area

IMMUNOLOGY

MEDICINE, RESEARCH & EXPERIMENTAL

ONCOLOGY

CiteScore

7.50

View Trend

CiteScore Ranking

Category	Quartile	Rank
Pharmacology, Toxicology and Pharmaceutics - Pharmacology	Q1	#75/301
Pharmacology, Toxicology and Pharmaceutics - Immunology and Allergy	Q2	#70/211
Pharmacology, Toxicology and Pharmaceutics - Immunology	Q2	#79/217
Pharmacology, Toxicology and Pharmaceutics - Cancer Research	Q2	#80/214

Web of Science Core Collection

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

Category (Journal Citation Reports 2023)	Quartile
IMMUNOLOGY - SCIE	Q3
MEDICINE, RESEARCH & EXPERIMENTAL - SCIE	Q3
ONCOLOGY - SCIE	Q2

H-index

Country/Area of Publication

UNITED STATES

Publisher

Lippincott Williams and Wilkins Ltd.

Publication Frequency

Monthly

Year Publication Started

1997

Annual Article Volume

Open Access

Contact

LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621

Popular journals in the same field
Recent articles

Predicting PD-L1 Status in Solid Tumors Using Transcriptomic Data and Artificial Intelligence Algorithms: (2023) Ahmad Charifa, Alfonso Lam, Hong Zhang, Andrew Ip, Andrew Pecora, Stanley Waintraub, Deena Graham, Donna McNamara, Martin Gutierrez, Andrew Jennis, Ip...

Too Much of a Good Thing: The Association of Elevated Vitamin B12 Levels and Outcomes in Patients With Cancer Treated With Immunotherapy: (2023) Ilit Turgeman, Anat Reiner Benaim, Stav Regev -Tsur, Shahar Turgeman, Mahmud Abu Amna, Omar Badran, Gil Bar-Sela

Durvalumab-induced Pure White Cell Aplasia: (2023) Ji Lin, Paola Rodriguez-Martinez, Thein Hlaing Oo, Shuyu E, Jeffrey Jorgensen, Cristhiam M. Rojas-Hernandez

Three-Year Overall Survival of Patients With Advanced Non–Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study): (2023) Chantal Decroisette, Laurent Greillier, Hubert Curcio, Maurice Pérol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, Remi Veillon, Sabine Vie...

Antigen-loaded Monocyte Administration and Flt3 Ligand Augment the Antitumor Efficacy of Immune Checkpoint Blockade in a Murine Melanoma Model: (2023) Vincent M. D’Anniballe, Min-Nung Huang, Benjamin D. Lueck, Lowell T. Nicholson, Ian McFatridge, Michael D. Gunn

Immune-Related Sclerosing Cholangitis and Subsequent Pyogenic Liver Abscesses in Two Patients With Melanoma Treated by Triplet Therapy: A Case Report: (2023) Viola Schön, Daniel Stocker, Christoph Jüngst, Reinhard Dummer, Egle Ramelyte

Laser Interstitial Thermal Therapy Induces Robust Local Immune Response for Newly Diagnosed Glioblastoma With Long-term Survival and Disease Control: (2023) Jay S. Chandar, Shovan Bhatia, Shreya Ingle, Mynor J. Mendez Valdez, Dragan Maric, Deepa Seetharam, Jelisah F. Desgraves, Vaidya Govindarajan, Lekhaj...

Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors: (2023) Yong Fan, Juan Zhao, Yue Mi, Zhening Zhang, Yan Geng, Liqun Zhou, Lin Shen, Zhuoli Zhang

Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models: (2023) Mei Yang, Tian Guan, Chun-Fa Chen, Li-Fang He, Hao-Ming Wu, Ren-Dong Zhang, Yun Li, Yan-Chun Lin, Haoyu Zeng, Jun-Dong Wu

Surfaceome Profiling Suggests Potential of Anti-MUC1×EGFR Bispecific Antibody for Breast Cancer Targeted Therapy: (2023) Mona Pourjafar, Massoud Saidijam, Michaela Miehe, Rezvan Najafi, Meysam Soleimani, Edzard Spillner

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started